Greater OS Benefit Among Patients with Advanced Cancer Treated with Matched Targeted Therapy Based on Biomarkers Identified by ctDNA Genotyping By Ogkologos - November 11, 2024 692 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SCRUM-Japan GOZILA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR FDA Grants Accelerated Approval to Adagrasib with Cetuximab for KRAS G12C-mutated... July 15, 2024 Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Prolongs OS Among... November 8, 2024 Trialling a new way to boost CAR T-cell therapy June 23, 2021 Characterisation of KRAS, Including KRAS G12C, Mutations in Gastrointestinal and Metastatic... July 2, 2021 Load more HOT NEWS BRAF/MEK Inhibition May Be a Viable Treatment Strategy Across the Majority... Mom Is Outraged After Finding Out Her Mother-In-Law Changed The Baby’s... Dwayne Johnson Sends Special “Moana” Message To 3-Yr-Old Battling Cancer. Foodie Friday: It’s Berry Season!
